Victory Square Technologies Posts Q3 2025 Results — Cash, Growth, and Big Moves Ahead

Victory Square Technologies Inc. (CSE: VST / FSE: 6F6 / OTC Pink: VSQTF) has published its financial results for the three- and nine-month periods ended September 30, 2025 — and delivered an ambitious update on its expanding global portfolio. 📊 Q3 2025 Financial Snapshot Adjusted Revenue: US$ 12.83 million GAAP Revenue: US$ 10.52 million Gross Margin: US$ 2.33 million Adjusted EBITDA: US$ 1.26 million Cash & Marketable Securities (as of quarter-end): US$ 25.91 million For the first 9 months of 2025: Adjusted Revenue US$ 26.71 million, GAAP Revenue US$ 20.44 million 🔧 What’s Going On Behind the Numbers According to CEO Shafin Diamond Tejani, Q3 was driven by strong execution across the company’s diverse businesses — from digital health to biotech, pet wellness, climate tech, and immersive tech. Here are the biggest developments: Hydreight Technologies Inc. — Victory Square’s flagship digital‑health arm — continued its national expansion and remained the company’s operational engine. Insu Therapeutics Inc. is advancing development of an oral insulin pill, with plans targeting first‑in‑human studies (subject to regulatory approval) in 2026. Pawsible Ventures Inc. launched a US$10 million fund and studio to back ventures in pet health & wellness — marking the company’s broader push beyond human health. XR Immersive Tech boosted efforts to integrate immersive technologies into health‑related IP — from virtual diagnostics to 3D health data visualization and patient‑education tools. Other portfolio moves include divesting non‑core assets (e.g. sale of AI fintech tools and a previous business called BlockX) and executing a normal course issuer bid (NCIB) to repurchase up to 5,000,000 common shares. 🔮 What’s Next? Looking ahead, Victory Square aims to: Back continued growth in its core verticals: Hydreight (digital health), VSDHOne / VSDH platforms, pet wellness via Pawsible, XR Immersive health tech, and Insu’s oral‑insulin program. Keep driving value via selective capital‑recycling and share‑buyback activity. Build long-term, sustainable value by backing early‑stage companies that can scale globally across tech, health, wellness, and climate sectors. Bottom line: Victory Square isn’t just showing healthy financials now — it’s laying the groundwork for a diversified growth engine that spans digital health, biotech, pet wellness, and immersive tech. #VictorySquare #Q32025Results #DigitalHealth #VentureBuilder #SlimScan #GrowthStocks #CANSLIM